Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
283.6 SEK | -0.21% |
|
+2.60% | +6.22% |
06-19 | Sobi Wins EU Approval for Hemophilia A Drug Altuvoct | MT |
06-19 | European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.22% | 9.09B | |
+2.99% | 94.76B | |
-4.34% | 37.58B | |
-10.41% | 33.3B | |
+75.79% | 27.92B | |
-14.61% | 15.85B | |
-3.46% | 13.79B | |
-12.31% | 11.51B | |
+184.77% | 10.9B | |
-54.13% | 9.27B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Sobi Wins EU Approval for Hemophilia A Drug Altuvoct